Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVDL Avadel Pharmaceuticals	$9.54 +3.9%	$9.05	$6.38 ▼ $17.30	$888.06M	1.45	1.30 million shs	1.52 million shs
CKPT Checkpoint Therapeutics	$4.26	$4.17	$1.87 ▼ $4.50	$370.71M	1.18	1.46 million shs	N/A
EOLS Evolus	$9.38 +1.1%	$10.25	$8.67 ▼ $17.82	$598.33M	1	749,389 shs	900,491 shs
REPL Replimune Group	$9.23 -0.4%	$8.87	$6.44 ▼ $17.00	$714.59M	0.63	853,939 shs	794,173 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVDL Avadel Pharmaceuticals	+3.92%	+0.42%	+4.49%	+16.34%	-36.44%
CKPT Checkpoint Therapeutics	0.00%	0.00%	+1.67%	+4.93%	+136.67%
EOLS Evolus	+1.08%	-5.82%	-3.10%	-24.54%	-11.09%
REPL Replimune Group	-0.43%	-6.10%	+10.54%	-13.66%	+8.59%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVDL Avadel Pharmaceuticals	1.7919 of 5 stars	3.5	1.0	0.0	1.4	1.7	0.6
CKPT Checkpoint Therapeutics	2.1517 of 5 stars	1.2	4.0	4.2	1.1	0.8	0.0
EOLS Evolus	3.8784 of 5 stars	3.5	1.0	3.5	1.7	3.3	0.6
REPL Replimune Group	4.2839 of 5 stars	3.6	3.0	4.5	1.8	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVDL Avadel Pharmaceuticals	3.00	Buy	$18.17	90.43% Upside
CKPT Checkpoint Therapeutics	2.33	Hold	$4.33	1.72% Upside
EOLS Evolus	3.00	Buy	$23.75	153.20% Upside
REPL Replimune Group	3.13	Buy	$20.83	125.71% Upside

Current Analyst Ratings Breakdown

Latest CKPT, EOLS, AVDL, and REPL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/20/2025	REPL Replimune Group	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight
6/2/2025	REPL Replimune Group	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$14.00 ➝ $22.00
5/8/2025	AVDL Avadel Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$19.00 ➝ $19.00
5/8/2025	EOLS Evolus	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00 ➝ $22.00
4/17/2025	EOLS Evolus	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$21.00
4/10/2025	EOLS Evolus	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00 ➝ $27.00
4/9/2025	AVDL Avadel Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$19.00 ➝ $19.00
4/9/2025	EOLS Evolus	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00 ➝ $22.00
3/31/2025	CKPT Checkpoint Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.80 ➝ $4.80

(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVDL Avadel Pharmaceuticals	$169.12M	5.46	N/A	N/A	$0.77 per share	12.39
CKPT Checkpoint Therapeutics	$41K	9,041.59	N/A	N/A	($0.47) per share	-9.06
EOLS Evolus	$266.27M	2.27	N/A	N/A	$0.09 per share	104.22
REPL Replimune Group	N/A	N/A	N/A	N/A	$5.40 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVDL Avadel Pharmaceuticals	-$48.83M	-$0.27	N/A	159.00	N/A	-13.58%	-36.07%	-16.30%	8/6/2025 (Estimated)
CKPT Checkpoint Therapeutics	-$51.85M	-$1.29	N/A	∞	N/A	N/A	N/A	-659.07%	8/11/2025 (Estimated)
EOLS Evolus	-$50.42M	-$0.89	N/A	N/A	N/A	-20.40%	-759.04%	-20.14%	7/30/2025 (Estimated)
REPL Replimune Group	-$247.30M	-$3.07	N/A	N/A	N/A	N/A	-57.98%	-45.21%	8/6/2025 (Estimated)

Latest CKPT, EOLS, AVDL, and REPL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/22/2025	Q4 2025	REPL Replimune Group	-$0.75	-$0.82	-$0.07	-$0.82	N/A	N/A
5/13/2025	Q1 2025	CKPT Checkpoint Therapeutics	-$0.10	-$0.19	-$0.09	-$0.19	$4.53 million	N/A
5/7/2025	Q1 2025	AVDL Avadel Pharmaceuticals	-$0.07	-$0.05	+$0.02	-$0.05	$50.57 million	$52.51 million
3/28/2025	Q4 2024	CKPT Checkpoint Therapeutics	-$0.22	-$0.69	-$0.47	-$0.69	N/A	$0.04 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVDL Avadel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CKPT Checkpoint Therapeutics	N/A	N/A	N/A	N/A	N/A
EOLS Evolus	N/A	N/A	N/A	N/A	N/A
REPL Replimune Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVDL Avadel Pharmaceuticals	N/A	2.73	2.33
CKPT Checkpoint Therapeutics	N/A	0.29	0.29
EOLS Evolus	22.00	2.34	2.16
REPL Replimune Group	0.17	7.95	7.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVDL Avadel Pharmaceuticals	69.19%
CKPT Checkpoint Therapeutics	22.00%
EOLS Evolus	90.69%
REPL Replimune Group	92.53%

Insider Ownership

Company	Insider Ownership
AVDL Avadel Pharmaceuticals	5.20%
CKPT Checkpoint Therapeutics	2.10%
EOLS Evolus	6.10%
REPL Replimune Group	8.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVDL Avadel Pharmaceuticals	70	96.74 million	91.71 million	Optionable
CKPT Checkpoint Therapeutics	10	87.02 million	47.81 million	Optionable
EOLS Evolus	170	64.48 million	60.54 million	Optionable
REPL Replimune Group	210	77.09 million	70.30 million	Optionable

CKPT, EOLS, AVDL, and REPL Headlines

Recent News About These Companies

Cantor Fitzgerald Begins Coverage on Replimune Group (NASDAQ:REPL)

June 22 at 1:13 AM | americanbankingnews.com

Cantor Fitzgerald Initiates Coverage of Replimune Group (REPL) with Overweight Recommendation

June 21 at 12:04 AM | msn.com

Replimune Group (NASDAQ:REPL) Coverage Initiated at Cantor Fitzgerald

June 20, 2025 | marketbeat.com

Replimune Group, Inc. (NASDAQ:REPL) Shares Sold by Bank of America Corp DE

June 14, 2025 | marketbeat.com

Replimune Group, Inc. Grants Inducement Equity Awards to New Employees Under 2025 Plan

June 6, 2025 | quiverquant.com

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 6, 2025 | globenewswire.com

Replimune Group (NASDAQ:REPL) Shares Gap Up - Time to Buy?

June 4, 2025 | marketbeat.com

Wellington Management Group LLP Grows Position in Replimune Group, Inc. (NASDAQ:REPL)

June 3, 2025 | marketbeat.com

Piper Sandler Issues Positive Forecast for Replimune Group (NASDAQ:REPL) Stock Price

June 2, 2025 | marketbeat.com

Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

June 1, 2025 | globenewswire.com

Two Sigma Investments LP Buys 33,346 Shares of Replimune Group, Inc. (NASDAQ:REPL)

June 1, 2025 | marketbeat.com

Replimune Group, Inc. (NASDAQ:REPL) Receives Consensus Rating of "Buy" from Analysts

June 1, 2025 | marketbeat.com

Replimune Group (NASDAQ:REPL) Stock Price Down 5.9% - Time to Sell?

May 31, 2025 | marketbeat.com

Replimune Group (NASDAQ:REPL) Stock Price Up 5.4% - Here's Why

May 30, 2025 | marketbeat.com

Replimune Group, Inc. (NASDAQ:REPL) Shares Acquired by Nuveen Asset Management LLC

May 30, 2025 | marketbeat.com

Replimune to Present at the 2025 Jefferies Global Healthcare Conference

May 29, 2025 | globenewswire.com

HC Wainwright Estimates Replimune Group Q3 Earnings

May 27, 2025 | marketbeat.com

Leerink Partnrs Estimates Replimune Group Q1 Earnings

May 27, 2025 | marketbeat.com

Replimune’s SWOT analysis: biotech firm’s stock poised for growth amid FDA review

May 26, 2025 | investing.com

Replimune Group, Inc. (NASDAQ:REPL) Shares Acquired by Woodline Partners LP

May 25, 2025 | marketbeat.com

Millennium Management LLC Acquires 34,841 Shares of Replimune Group, Inc. (NASDAQ:REPL)

May 25, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CKPT, EOLS, AVDL, and REPL Company Descriptions

Avadel Pharmaceuticals NASDAQ:AVDL

$9.54 +0.36 (+3.92%)

Closing price 06/23/2025 04:00 PM Eastern

Extended Trading

$9.41 -0.13 (-1.31%)

As of 06/23/2025 04:53 PM Eastern

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Checkpoint Therapeutics NASDAQ:CKPT

$4.26 0.00 (0.00%)

As of 05/30/2025

Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

Evolus NASDAQ:EOLS

$9.38 +0.10 (+1.08%)

Closing price 06/23/2025 04:00 PM Eastern

Extended Trading

$9.34 -0.04 (-0.44%)

As of 06/23/2025 07:25 PM Eastern

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Replimune Group NASDAQ:REPL

$9.23 -0.04 (-0.43%)

Closing price 06/23/2025 04:00 PM Eastern

Extended Trading

$9.24 +0.01 (+0.16%)

As of 06/23/2025 04:20 PM Eastern

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time